Is Boceprevir Cost-Effective for Previously Treated Hepatitis C Patients?

Published Oct 8, 2013
Pittsburgh, PA, USA - Around 3 million people in the United States are chronically infected with hepatitis C virus (HCV), which is the leading cause of liver cancer and liver transplant. Unlike hepatitis A and B, no vaccine is currently available for hepatitis C. After a gap of 10 years, boceprevir, belonging to the class of protease inhibitors, was approved for HCV treatment in 2011. The new treatment increased the cure rates, however, it is expensive and has several side effects. The cost-effectiveness of treating patients with boceprevir who failed prior treatment is not known in the U.S. A team of researchers (including health economists and hepatologists) from the University of Pittsburgh and Merck developed a Markov state-transition model simulating the clinical trials and the natural history of hepatitis C disease. Using this model, the researchers determined that boceprevir-based treatment was cost-effective in treating HCV-infected patients who failed prior treatment, irrespective of prior treatment response, disease stage and genetic profile. Their findings showed that boceprevir-based treatment is expected to increase the quality-adjusted life years (QALY) by 0.85-1.01 years. In addition, the new treatment can reduce the lifetime incidence of decompensated cirrhosis, liver cancer, liver-transplant and liver-related death by 41-52% in comparison with the peginterferon-ribavirin. At the average drug cost of $53,000, the incremental cost-effectiveness ratio of new treatment compared to the standard of care was $35,000 per QALY in early stages of disease and $10,000 per QALY in cirrhosis stage. Jagpreet Chhatwal, PhD, now an Assistant Professor of Health Services Research at The University of Texas MD Anderson Cancer Center in Houston, and the lead-author of the study said, “We developed a modeling framework that incorporates data from clinical trials, natural history of hepatitis C disease, costs, and quality of life to evaluate the cost-effectiveness of new treatment regimens. The new treatment, although expensive, can reduce the downstream costs associated with liver transplant and liver cancers, and improve the length and quality of life of the patients.”  The full study, “Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype I Infection in the United States” is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org 

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×